CAICaris Life Sciences, Inc.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +36% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 9, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 30, 2026, a few days of normal trading to cover. Up 4.2% since the previous count, down from 5.0% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CAI is trading
Caris Life Sciences, Inc. is −9.8% over the past year while the S&P 500 is +18%: 27 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +36%
vs 200-day average · a clear uptrend
- RSI (14)
- 43
RSI (14) · neutral
- Below its 52-week high
- 9.9%
Below its 52-week high
Details›
- Last close2026-10-12
- $29.70
- 1 monthS&P 500 +1.8%
- +22%
- 1 yearS&P 500 +18%
- −9.8%
- vs 50-day average$25.83
- +15%
- 52-week high
- $32.95
- 52-week low
- $14.55
- Annualised volatility
- 66%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-09
- −$26M
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry